endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.62751/2713-0177-2024-5-3-06endofocus-101Research ArticleОБЗОР ЛИТЕРАТУРЫLITERATURE REVIEWИнгибиторы натрий-глюкозного котранспортера 2 типа и неалкогольная жировая болезнь печениSodium-glucose co-transporter type 2 inhibitors and non-alcoholic fatty liver diseasehttps://orcid.org/0009-0001-2444-8251ШубинаК. М.ShubinaK. M.

Шубина Ксения Михайловна – аспирант кафедры госпитальной терапии им. академика Г.И. Сторожакова ИКМ

г. Москва

Kseniya M. Shubina – Postgraduate student

Moscow

ksu664@gmail.comhttps://orcid.org/0000-0001-5416-8579АлиеваА. М.AlievaA. M.

Алиева Амина Магомедовна – к.м.н., доцент кафедры госпитальной терапии им. академика Г.И. Сторожакова ИКМ

г. Москва

Amina M. Alieva – C. Sci. (Med.)

Moscow

amisha_alieva@mail.ruhttps://orcid.org/0000-0003-1699-0881НикитинИ. Г.NikitinI. G.

Никитин Игорь Геннадиевич – д.м.н., профессор, заведующий кафедрой госпитальной терапии им. академика Г.И. Сторожакова ИКМ

г. Москва

Igor G. Nikitin – Dr. of Sci. (Med), Professor

Moscow

igor.nikitin.64@mail.ruФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииPirogov Russian National Research Medical University202407112024534554Copyright © Шубина К.М., Алиева А.М., Никитин И.Г., 20242024Шубина К.М., Алиева А.М., Никитин И.Г.Shubina K.M., Alieva A.M., Nikitin I.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/101

Неалкогольная жировая болезнь печени (НАЖБП) – общий термин, включающий доброкачественный стеатоз и неалкоголный стеатогепатит (НАСГ) с возможностью развития фиброза печени (ФП), цирроза печени (ЦП) и гепатоцеллюлярной карциномы (ГЦК), являющихся естественными эволюционными стадиями заболевания. Широкая распространенность НАЖБП – чрезвычайно актуальная медико-социальная проблема для общественных систем здравоохранения большинства стран мира. Изучение вопросов профилактики НАЖБП или замедления прогрессирования заболевания становится глобальной задачей для научного сообщества и практического здравоохранения. Изменение образа жизни остается главной рекомендацией лечения, несмотря на различные попытки проведения клинических исследований препаратов широкого фармакологического спектра. Среди последних перспективными представляются ингибиторы натрий-глюкозного котранспортера типа 2 (иНГЛТ-2). Процессы, регулируемые НГЛТ-2, такие как стресс эндоплазматического ретикулума (ЭР) и окислительный стресс, вялотекущее воспаление, аутофагия и апоптоз, играют важную роль в патогенезе НАЖБП. В этом обзоре суммированы современные представления о патофизиологии НАЖБП, при этом особое внимание уделено актуальным данным исследований в экспериментальных моделях и клинической практики о потенциальном действии иНГЛТ-2 на развитие и прогрессирование НАЖБП. Учитывая эти данные, дальнейшие исследования будут способствовать более полному пониманию точных механизмов, лежащих в основе патогенеза НАЖБП, и потенциального влияния иНГЛТ-2 при лечении этого заболевания.

Non–alcoholic fatty liver disease (NAFLD) is a general term that includes benign steatosis and non-alcoholic stethohepatitis (NASH) with the possibility of developing liver fibrosis (LF), liver cirrhosis (LC) and hepatocellular carcinoma (HCC), which are natural evolutionary stages of the disease. The widespread prevalence of NAFLD is an extremely urgent medical and social problem for public health systems in most countries of the world. The study of the prevention of NAFLD or slowing the progression of the disease is becoming a global task for the scientific community and practical healthcare. Lifestyle changes remain the main recommendation of treatment, despite various attempts to conduct clinical trials of drugs of a wide pharmacological spectrum. Among the latter, sodium-glucose co-transporter type 2 inhibitors (iNGLT-2) are becoming a promising direction. Processes regulated by the sodium-glucose co-transporter (NGL-2), such as stress on the endoplasmic reticulum (ER) and oxidative stress, sluggish inflammation, autophagy and apoptosis, play an important role in the pathogenesis of NAFLD. In this review, we summarize the current understanding of the pathophysiology of NAFLD and focus on the potential impact of iNGLT-2 on the development and progression of NAFLD, providing current research data in experimental models and clinical practice. Given these findings, further research will contribute to our fuller understanding of the exact mechanisms underlying the pathogenesis of NAFLD and the potential effects of iNGLT-2 in the treatment of NAFLD.

неалкогольная жировая болезнь печениингибиторы натрий-глюкозного котранспортера типа 2метаболический синдромсахарный диабет 2 типаnon-alcoholic fatty liver diseasetype 2 sodium-glucose co-transporter inhibitorsmetabolic syndrometype 2 diabetes mellitusReferencesAndrustakos T, Nasiri-Ansari N, Bakasis AD et al. SGLT-2 inhibitors in NAFLD: Expanding their role beyond diabetes and cardioprotection. Int J Mol Sci. 2022; 23(6): 3107. doi: 10.3390/ijms23063107.Andrustakos T, Nasiri-Ansari N, Bakasis AD et al. SGLT-2 inhibitors in NAFLD: Expanding their role beyond diabetes and cardioprotection. Int J Mol Sci. 2022; 23(6): 3107. doi: 10.3390/ijms23063107.Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1): 73–84. doi: 10.1002/hep.28431.Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1): 73–84. doi: 10.1002/hep.28431.Hui JM, Kench JG, Chitturi S et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003; 38(2): 420–27. doi: 10.1053/jhep.2003.50320.Hui JM, Kench JG, Chitturi S et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003; 38(2): 420–27. doi: 10.1053/jhep.2003.50320.Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002; 123(1): 134–40. doi: 10.1053/gast.2002.34168.Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002; 123(1): 134–40. doi: 10.1053/gast.2002.34168.Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014; 2(11): 901–10. doi: 10.1016/S2213-8587(14)70032-4.Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014; 2(11): 901–10. doi: 10.1016/S2213-8587(14)70032-4.Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease. BMJ. 2021; 372: m4747. doi: 10.1136/bmj.m4747.Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease. BMJ. 2021; 372: m4747. doi: 10.1136/bmj.m4747.European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6): 1388–402. doi: 10.1016/j.jhep.2015.11.004.European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6): 1388–402. doi: 10.1016/j.jhep.2015.11.004.Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328–57. doi: 10.1002/hep.29367.Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328–57. doi: 10.1002/hep.29367.Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7): 1999–2014.e1. doi: 10.1053/j.gastro.2019.11.312.Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7): 1999–2014.e1. doi: 10.1053/j.gastro.2019.11.312.Fouad Y, Waked I, Bollipo S et al. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’ Liver Int. 2020; 40(6): 1254–61. doi: 10.1111/liv.14478.Fouad Y, Waked I, Bollipo S et al. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’ Liver Int. 2020; 40(6): 1254–61. doi: 10.1111/liv.14478.Rinaldi L, Pafundi PC, Galiero R et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review. Antioxidants. 2021; 10(2): 270. doi: 10.3390/antiox10020270.Rinaldi L, Pafundi PC, Galiero R et al. Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review. Antioxidants. 2021; 10(2): 270. doi: 10.3390/antiox10020270.Masarone M, Rosato V, Aglitti A et al. Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. PLoS ONE. 2017; 12(6): e0178473. doi: 10.1371/journal.pone.0178473.Masarone M, Rosato V, Aglitti A et al. Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. PLoS ONE. 2017; 12(6): e0178473. doi: 10.1371/journal.pone.0178473.Tanase DM, Gosav EM, Costea CF et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020; 2020: 3920196. doi: 10.1155/2020/3920196.Tanase DM, Gosav EM, Costea CF et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020; 2020: 3920196. doi: 10.1155/2020/3920196.Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol. 2014; 20(37): 13306–24. doi: 10.3748/wjg.v20.i37.13306.Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol. 2014; 20(37): 13306–24. doi: 10.3748/wjg.v20.i37.13306.Galiero R, Caturano A, Vetrano E et al. Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. Rev Cardiovasc Med. 2021; 22(3): 755–68. doi: 10.31083/j.rcm2203082.Galiero R, Caturano A, Vetrano E et al. Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. Rev Cardiovasc Med. 2021; 22(3): 755–68. doi: 10.31083/j.rcm2203082.Petta S, Argano C, Colomba D et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease. J Hepatol. 2015; 62(4): 928–33. doi: 10.1016/j.jhep.2014.11.030.Petta S, Argano C, Colomba D et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease. J Hepatol. 2015; 62(4): 928–33. doi: 10.1016/j.jhep.2014.11.030.U.S. Food and Drug Administration (FDA) FDA Approves New Treatment for a Type of Heart Failure. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failureU.S. Food and Drug Administration (FDA) FDA Approves New Treatment for a Type of Heart Failure. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failureU.S. Food and Drug Administration (FDA) FDA Approves Treatment for Chronic Kidney Disease. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-diseaseU.S. Food and Drug Administration (FDA) FDA Approves Treatment for Chronic Kidney Disease. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-chronic-kidney-diseaseKim JW, Lee YJ, You YH et al. Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and alpha-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. J Cell Biochem. 2018; 120(5): 8534–46. doi: 10.1002/jcb.28141.Kim JW, Lee YJ, You YH et al. Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and alpha-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. J Cell Biochem. 2018; 120(5): 8534–46. doi: 10.1002/jcb.28141.Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) Metabolism. 2016; 65(8): 1038–48. doi: 10.1016/j.metabol.2015.12.012.Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) Metabolism. 2016; 65(8): 1038–48. doi: 10.1016/j.metabol.2015.12.012.Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2018; 68(2): 268–79. doi: 10.1016/j.jhep.2017.09.003.Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2018; 68(2): 268–79. doi: 10.1016/j.jhep.2017.09.003.

The authors declare that there are no conflicts of interest present.